A New Alzheimer’s Therapy?

Results from a human clinical trial demonstrate LSD microdosing to be safe and tolerable, but it is too early for clear efficacy data
Results from a human clinical trial demonstrate LSD microdosing to be safe and tolerable, but it is too early for clear efficacy data

New results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing Lysergic Acid Diethylamide (LSD). This Phase 1 trial is the first step in testing whether these kinds of psychedelic microdose methods could be useful as a therapeutic approach for treating Alzheimer’s disease, and while the early data doesn’t identify significant cognitive benefits in microdosing, it certainly demonstrates the method is safe enough to proceed to larger efficacy trials. read more

A Single Injection for Peanut Allergy?

Medical scientists at Stanford University have set out to explore the potential of a drug called etokimab in treating peanut allergies
Medical scientists at Stanford University have set out to explore the potential of a drug called etokimab in treating peanut allergies

The long pursuit of a treatment for peanut allergy is littered with false dawns, but there are also some promising possibilities on the horizon, including one currently on the cusp of FDA approval. Another has just emerged via a promising early trial at Stanford University, where scientists found a single injection of an antibody treatment enabled those with severe allergies to stomach peanuts for some time. read more